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ABSTRACT
Food allergy can influence the development of colorectal cancer, although 
the underlying mechanisms are unclear. While mast cells (MC) store and secrete 
histamine, immature myeloid cells (IMC) are the major site of histidine decarboxylase 
(HDC) expression, the enzyme responsible for histamine production. From our earlier 
work, we hypothesized that histamine is central to the association between allergy 
and colorectal carcinogenesis through its influence on the MC-MDSC axis. Here, we 
show that in wild type (WT) mice, ovalbumin (OVA) immunization elicits a typical 
TH2 response. In contrast, in HDC−/− mice, the response to OVA allergy is skewed 
towards infiltration by IL-17 expressing MCs. This response is inhibited by histamine 
treatment. The HDC−/− allergic IL-17-expressing MCs promote MDSC proliferation and 
upregulation of Cox-2 and Arg-1. OVA allergy in HDC−/− mice increases the growth 
of colon tumor cells in both the MC38 tumor cell implantation model and the AOM/
DSS carcinogenesis model. Taken together, our results show that histamine represses 
IL-17-expressing MCs and their subsequent activation of MDSCs, attenuating the risk 
of colorectal cancer in the setting of food allergy. Targeting the MC-MDSC axis may 
be useful for cancer prevention and treatment in patients, particularly in those with 
food allergy.
INTRODUCTION
Although mast cells (MCs) are known for rapid 
histamine secretion and degranulation in IgE-mediated 
immunity, it is now appreciated that MCs also contribute 
to cancer development (reviewed in [1–3]). In particular, 
MCs influence the polarity of TH1, TH2, and TH17 cells by 
regulating the maturation of antigen presenting cells 
[4, 5] and the release of proinflammatory cytokines 
[3, 6]. Proinflammatory cytokines produced by MCs may 
promote carcinogenesis through direct tumor stimulation 
as well as through their support of immune suppressive 
cells, such as regulatory T (Treg) cells and myeloid-
derived suppressor cells (MDSC) [6–9]. MDSCs arise 
from CD11b+Gr1+ immature myeloid cells (IMC) found 
within the tumor microenvironment. MDSCs promote 
carcinogenesis in part through T-cell suppression, 
which results in a loss in tumor immunity [10]. Recent 
studies suggest that MCs regulate the recruitment and 
immunoregulatory activity of MDSCs [11, 12]. MCs also 
play critical roles in epithelial cell activation, T helper cell 
polarization and intraepithelial stromal cell remodeling 
[13–16]. Given these many diverse functions, MCs could 
play an important role in promoting tumor development.
The intestine contains a broad range of IL-17-
expressing cells, such as innate-like T cells, neutrophils, 
eosinophils, invariant natural killer T (iNKT) cells, αβ 
and γδ T cells, and lymphoid tissue inducer-like cells 
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(LTi-like) cells [17–20]. Recently, MCs were also shown 
to produce IL-17 in human cancer [9, 21–23]. IL-17 is a 
major proinflammatory cytokine, and is known to stimulate 
myeloid cells, including tumor-promoting MDSCs [24, 25]. 
The mechanisms involved in the overproduction of IL-17 
in the tumour microenvironment, however, have not been 
fully investigated.
Tissue histamine promotes angiogenesis, neuro-
transmission, gastric acid secretion, myeloid cell 
differentiation, and innate immunity [26, 27]. In addition, 
histamine has a well established role in modulating 
inflammatory reactions, including intestinal food allergy 
[31, 32]. MCs store and secret histamine yet are also 
regulated by histamine [33, 34]. Interestingly HDC, the 
enzyme generating endogenous histamine, is primarily 
expressed by CD11b+Gr1+ IMCs, rather than MCs 
[28]. IMCs are a group of innate immune cells that are 
often localized adjacent to MCs in the gut, and help to 
balance immune responses during persistent unresolved 
inflammation [10, 35]. In previous work, we found 
that knockout of HDC, the chief enzyme that generates 
histamine in CD11b+Gr1+ cells, increases MDSCs 
and tumorigenicity in the azoxymethane (AOM) and 
dextran sodium sulfate (DSS) model [28]. A number of 
studies have implicated allergy, a histamine-mediated 
disorder, in the modulation of cancer risk (reviewed in 
[29, 30]). We hypothesized that histamine would help 
protect patients with food allergy from developing 
colorectal cancer. We found that HDC gene deletion 
promoted colorectal carcinogenesis through increased 
MC production of IL-17, leading to an expansion of 
CD11b+Gr1+ MDSCs and suppression of CD8 cells. 
Interestingly, this increased tumor susceptibility was 
rescued by treatment with or replacement of histamine. 
This study identifies a histamine-dependent link between 
food allergy and colorectal carcinogenesis, and highlights 
a new pathway to target in the prevention and treatment 
of bowel cancer.
RESULTS
IL4/IL4Rα axis mediates WT but not HDC−/− 
OVA intestinal allergy
To better understand the interrelationship between 
histamine-secreting MC and HDC-expressing IMCs 
in food allergy and colorectal cancer, we treated WT 
C57BL/6 and HDC-EGFP mice with 30 ug i.g. and 50 
ug i.p. of OVA daily for 10 consecutive days [36]. As 
expected, serum IL-4 levels and small intestinal mRNA 
expression of IL-4 receptor α chain (IL-4Rα) were 
significantly increased in OVA allergic mice (Figure 1A). 
In addition, in OVA treated HDC-EGFP mice, in which 
EGFP fluorescence identifies CD11b+Gr1+ HDC-
expressing cells [28], we detected numerous circulating 
and intestinal EGFP+ myeloid cells (Figure 1B and 1C). 
Moreover, HDC mRNA levels were upregulated in sorted 
small intestinal CD11b+Gr1+ IMCs (Figure 1D).
It has been shown previously that TH2 cell derived 
IL-4 activates CD11b+Gr1+ cells through its receptor, 
IL4Rα [37, 38]. Consistently, we also detected elevated 
IL4Ra mRNA levels in small intestinal CD11b+Gr1+ cells 
of OVA-treated mice compared with PBS treated controls 
(Figure 1E). A causal link has been suggested between 
allergic histamine release and cytokine production of T 
helper cells, given that histamine receptor(s) knockout 
mice exhibit similar defects in T helper cell activation on 
common allergic signals [39–41]. To investigate whether 
histamine deficiency alters myeloid cell activation in the 
OVA intestinal allergy model, we crossed HDC knockout 
mice (HDC−/−) with HDC-EGFP and subjected them to the 
same OVA regimen. Although HDC−/− mice showed an 
attenuated OVA IgE response (Supplementary Figure S1A), 
surprisingly HDC-EGFP+ IMCs in the small intestine 
remained highly abundant (Supplementary Figure S1B), 
despite the absence of any increase in serum IL-4 levels 
(Supplementary Figure S1C). The CD11b+Gr1+ cells in 
the HDC−/− mice functionally resembled MDSCs, with 
10-fold greater expression of Arginase 1 (Arg-1) compared 
to CD11b+Gr1+ cells from WT mice treated with the 
same OVA regimen (Supplementary Figure S1D). The 
differences between WT and HDC−/− mice in response to 
OVA immunization suggested that histamine might mediate 
the activity of HDC−/− CD11b+Gr1+ cells. This led us to 
investigate MCs, the principal histamine secreting cell 
type. In the non-immunized (PBS control) HDC−/− mice, 
we found only rare tryptase+ MCs in the small intestine 
and colon, consistent with previous data that MC frequency 
is decreased in the peripheral tissues of HDC−/− mice 
[42, 43]. In OVA treated mice, however, there was a 
substantial accumulation of tryptase+ intestinal MCs. 
Notably, the colon MC numbers were increased over 10-
fold in the OVA immunized group compared to controls 
(Figure 1F). This was confirmed by flow cytometry 
(FcεRIα and c-kit staining, Supplementary Figure S1E). 
Collectively, these data suggest a link between HDC 
deficiency and the expansion of MCs and CD11b+Gr1+ 
cells during OVA allergy.
MC-derived IL-17 defines HDC−/− mice OVA 
allergy gut immunity
MC cytokine secretion recruits other myeloid 
cells and is a major contributor to inflammation [44, 45]. 
Although genetic deficiency of HDC impairs granule 
synthesis and homeostasis of MCs [42, 46], it is 
unknown whether HDC/histamine status affects MC 
cytokine production in an allergic setting. To address 
this question, cytokine gene expression in MCs from 
HDC−/− mice treated with OVA was assessed by qRT-
PCR, including TH1 cytokines (IFN-γ, IL-12p40, and 
TNFα), TH2 cytokines (IL-4, IL-5, IL10, and IL-13), 
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and proinflammatory cytokines (IL-1β, IL-23a, IL-6, 
and IL-17a). Our results revealed that in HDC−/− mice, 
there was marked induction by OVA of a number of MC-
derived proinflammatory cytokines, including several key 
cancer-promoting cytokines such as IL-1β and IL-6 and 
their downstream effector cytokine IL-17a (Figure 2A). 
Notably, these cytokines were not upregulated by OVA 
allergy in WT littermates (Supplementary Figure S2A). 
Thus, OVA treatment in the setting of histamine deficiency 
expanded and activated proinflammatory intestinal MCs.
Figure 1: OVA intestinal allergy in WT mice induces the production of IL-4 and accumulation of HDC-expressed 
CD11b+Gr1+ cells. WT mice (n = 5/group) were immunized with OVA (30 ug i.g. and 50 ug i.p.) or PBS. A. Serum IL-4 levels were 
quantified by ELISA (Left); Intestinal IL-4Ra expression was exanimated by qRT-PCR (Right). B. Representative flow plots of circulating 
HDC-EGFP+ in blood CD11b+Gr1+ cells (Left). Bar graph (Right) illustrates the proportions of cell populations with statistics. C. Imagines 
show EGFP+ cells from OVA treated and PBS controls small intestine frozen sections (Left). EGFP+ cells were enumerated in each observed 
microscopic field (Right). Expression of Hdc mRNA D. and IL-4Rα E. from sorted small intestine CD11b+Gr1+ cells. F. Representative 
images of small intestine and colon immunofluorescence staining for tryptase+ MCs in HDC−/− mice treated with either OVA or PBS (Left). 
Tryptase+ MCs were counted per microscopic field (Right). Data are representative of at least two independent experiments.
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To assess the overall contribution of MC-derived 
proinflammatory cytokines to the gut immune response 
to OVA allergy, and the role of histamine in modulating 
this response qRT-PCR analysis was performed on small 
intestinal tissue samples following OVA treatment. 
These studies revealed that, OVA allergy induced an up-
regulation of TH2 cytokines expression in WT mice but 
not in HDC−/− mice (Figure 2B). Instead, we observed 
Figure 2: Accumulation of IL-17 producing MCs in HDC−/− mice OVA intestinal allergy. A. Comparison of HDC−/− 
intestinal MC TH1, TH2, and inflammatory cytokine genes expression between OVA and PBS treated groups (n = 4/group). B. IL-4, IFN-γ, 
IL-12p40, TGF-β1 and TNF-α expression in WT (n = 3) and HDC−/− (n = 5) small intestine tissue, mice treated either OVA or PBS. 
C. IL-17 elevated in HDC−/− mice (n = 5) but not WT mice (n = 5) treated with OVA, bar graphs show IL-17a mRNA expression in the 
small intestine (Left), and IL-17a protein level in sera (Right). D. Representative frozen slides co-stained with tryptase and IL-17a from 
OVA allergy HDC−/− mice (n = 3) in small intestine and colon. Arrows indicate tryptase+IL-17+ MCs. Data are representative of 2–3 
independent experiments.
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much greater IL-17a expression in the intestine and in 
the circulation of HDC−/− mice (Figure 2C). Moreover, 
we identified a large number of tryptase+IL17a+ MCs 
in the small intestine and colon of HDC−/− OVA treated 
mice, particularly in the colon crypts and submucosa 
(Figure 2D). To exclude the possibility of IL-17 production 
from T cells (TH17 or Tc17 cells) [47], we assessed IL-17a 
mRNA expression in sorted small intestinal CD3+CD4+ 
and CD3+CD8+ T cells in response to OVA treatment. IL-
17a expression remained unchanged in both populations 
of T cells in HDC−/− mice following OVA sensitization 
(Supplementary Figure S2B). Although OVA treatment 
also increased MCs numbers in WT colon (Supplementary 
Figure S2C), only HDC−/− colon MCs showed increased 
IL-17a mRNA levels upon OVA induction (Supplementary 
Figure S2D). These data confirm that MCs are the key IL-
17 producing cell in the intestine following OVA challenge 
in histamine deficient mice.
Differentiation of IL-17-secreting MCs  
is regulated by histamine
To determine if histamine deficiency was largely 
responsible in the OVA allergy model for the increased 
production of MC IL-17, we attempted to rescue the 
phenotype through reconstitution with WT bone marrow-
derived mast cells (BMMCs) or through exogenous 
administration of histamine. BMMCs from WT or 
HDC−/− donors were infused into non-irradiated HDC−/− 
mice. Daily OVA administration was begun one day after 
adoptive transfer, and mice were sacrificed 10 days later. 
Mice infused with WT MCs showed a significantly lower 
level of IL-17 expression in the small intestine compared to 
mice infused with HDC−/− MCs (Figure 3A). Exogenous 
histamine (5 mg/kg/d i.p.×1 mo) also significantly reduced 
intestinal FCεRIα+c-kit+ MCs in OVA sensitized mice 
(Figure 3B). Histamine treatment decreased serum IL-17 
levels (Figure 3C) and small intestine MC IL-17 mRNA 
expression compared to the control OVA treated group 
(Figure 3D). We also assessed the effect of histamine on 
MC IL-17 production by adding 5 × 10–6 M histamine to 
HDC−/− MC co-cultured with splenocytes and OVA323–339 
peptide. Again, we found that histamine reduced IL-
17 secretion in HDC−/− MC ex vivo (Figure 3E). Taken 
together, these data suggest that histamine deficiency 
promotes MC expansion and production of IL-17, 
leading to higher serum IL-17 levels following an allergic 
challenge. The replacement studies establish histamine as 
necessary for inhibition of allergic MC accumulation and 
pro-inflammatory cytokine secretion.
MC IL-17 promotes colorectal carcinogenesis in 
both subcutaneous and carcinogenesis models
Recent studies have suggested that proin-
flammatory IL-17 has a role in promoting colorectal 
tumorigenesis [24, 48]. Tumor-infiltrating MCs and 
MDSCs are commonly found in colorectal cancer 
(CRC) [3, 6, 12]. As we have identified MCs as a 
novel cellular source of IL-17 in OVA immunized 
HDC−/− mice, we sought to determine whether the IL-
17-secreting MCs in HDC−/− mice promote colorectal 
carcinogenesis and whether CD11b+Gr1+ MDSCs 
are involved. To investigate this, we injected MC38 
(C57BL/6) colon carcinoma tumor cells subcutaneously 
into HDC−/−;HDC-EGFP mice. One group of mice 
was immunized with OVA for 10d before subcutaneous 
inoculation of MC38 cells, followed by repeated 
daily doses of OVA for days 11–21 immediately prior 
to harvest. The control group of mice were sham 
immunized with PBS. We found that mice immunized 
with OVA had significantly larger tumors that contained 
a greater proportion of both MCs and HDC-GFP+ cells 
(Figure 4A and 4B). These findings suggested that in 
the setting of histamine deficiency, colorectal cancer 
is promoted by allergic immune response that involve 
accumulation of both MCs and MDSCs.
We extended these tumorigenicity studies to a 
primary colorectal carcinogenesis model. We injected 
HDC−/− mice with 10 mg/kg of AOM, followed by 7 d 
of exposure to 2.5% DSS in the drinking water in order to 
generate colorectal tumors [28]. Before and after AOM/
DSS treatment, we immunized mice with three 10d cycles 
of OVA or PBS. After the last cycle of OVA or PBS 
administration, IgE to OVA was only detectable in OVA 
treated group (Supplementary Figure S3A). Although 
both groups of mice developed colorectal tumors, OVA 
treated mice had significantly more colorectal tumors 
that exhibited higher grades of dysplasia and evidence of 
intramucosal carcinoma (Figure 4C). Furthermore, OVA-
treated mice had a greater proportion of MDSCs in their 
bone marrow, spleen and circulation (Figure 4D). Notably, 
the number of infiltrating MCs within colorectal tumors 
was significantly higher in the OVA group (Figure 4E). 
Finally, serum IL-17a and tumor MC IL-17a mRNA levels 
were significantly increased after OVA plus AOM/DSS 
versus AOM/DSS alone (Figure 4F). Collectively, our 
results suggest that in histamine deficient mice, IL-17-
expressing allergic MCs are capable of promoting CRC in 
part through recruitment of CD11b+Gr1+ cells.
HDC−/− MCs augment CD11b+Gr1+ 
immunosuppressive function
Given the marked expansion of CD11b+Gr1+ cells 
in OVA-induced tumors above, we wondered whether these 
cells are the immune-suppressive MDSCs known to promote 
cancer. To address this, we isolated splenocytes from OVA-
induced HDC−/− mice and treated the splenocytes ex vivo 
with OVA323–339 peptide with or without the addition of 
HDC−/− BMMCs. After 96 h, CD11b+Gr1+ cells were 
flow sorted, and the expression of cyclooxygenase-2 
Oncotarget32971www.impactjournals.com/oncotarget
Figure 3: Effect of histamine on the regulation of IL-17-secreting MC. A. HDC−/− mice (n = 5/group) infused with either WT 
or HDC−/− BMMCs followed by OVA administration. OVA allergy mice infused with WT BMMCs had decreased IL-17a expression in 
small intestine. B. Exogenous histamine treatment lower the proportion of intestinal MC (FCεRIα+c-kit+) in HDC−/− mice (n = 3/group) 
OVA allergy. C. Serum IL-17a levels in HDC−/− OVA immunized mice (n = 5/group) with or without exogenous histamine injection. 
D. IL-17a mRNA level decreased in sorted FCεRIα+c-kit+ intestinal MCs from histamine treated, OVA immunized HDC−/− mice (n = 5/
group). E. in vitro cultured HDC−/− MC and splenocytes induced with OVA323–339 peptide in the presence of histamine displayed reduced 
IL-17a level in supernatant. Data are representative of three independent experiments.
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(Cox-2), Arg-1, and Ki67 were determined by real-time 
qRT-PCR. Our data confirm that in the presence of OVA, 
HDC−/− BMMCs were able to induce proliferation and 
increase expression of Cox-2 and Arg-1 in CD11b+Gr1+ 
cells (Figure 5A), consistent with an MDSC phenotype. 
Additionally, secreted IL-17 was increased in the supernatant 
of OVA-treated splenocytes (Figure 5B). These results 
confirm that IL-17 expressing MCs are able to promote 
Figure 4: OVA intestinal allergy promote colorectal carcinogenesis in HDC−/− mice. A. Tumor diameter from MC38 colon 
carcinoma tumor cells injected HDC−/−;HDC-GFP mice. Mice (n = 8/group) treated with OVA exhibited bigger tumor diameter than 
PBS controls. B. Increased accumulation of MCs and HDC-EGFP+ myeloid cells within MC38 carcinoma in the group of mice treated 
with OVA. C. Schematic representation of the OVA immunization plus AOM/DSS carcinogenesis protocol (Upper panel). Representative 
macroscopic pictures and H&E staining images from paraffin embedded colon tissue of tumor mice (n = 10/group, Lower panel). The 
number of tumors with statistics presented by bar picture (Right). D. Flow cytometry analysis of CD11b+Gr1+ MDSCs proportion in 
CD45+ cells in OVA or PBS plus AOM/DSS treated mice (n = 10/group) in blood, spleen, bone marrow, and colon tumor. E. Representative 
tryptase immunofluorescence staining from tumor-bearing mice colon frozen sections. F. OVA immunization increases serum IL-17a level 
and IL-17a mRNA expression in sorted tumor MCs from AOM/DSS colorectal carcinogenesis mice (n = 10/group). Data are representative 
from two independent experiments.
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the proliferation of CD11b+Gr1+ cells and enhance their 
immunosuppressive function through upregulation of Cox-
2 and Arg-1. These data also support a potential role for 
OVA-induced CD11b+Gr1+ myeloid cells in mediating 
suppressive effects on T cells, contributing to the observed 
increase in colorectal cancer.
We also investigated the influence of IL-17-
secreting MCs on MDSCs in the tumor microenvironment 
in vivo. We compared Cox-2, Arg-1, and Ki67 mRNA 
expression in tumor MDSCs in OVA immunized versus 
PBS-treated HDC−/− mice. Again, OVA treatment led 
to up-regulation of Cox-2, Arg-1 and Ki67 expression in 
MDSCs (Supplementary Figure S3B). Furthermore, OVA 
treated mice had fewer CD8+ T cells within the tumor 
margin compared to PBS treated controls (Figure 5C), 
suggesting that loss of cytotoxic T cells may be related to 
the promotion of carcinogenesis.
DISCUSSION
In this study, we found in a food allergy model an 
expansion of IL-17 producing MCs in the intestine. In 
the absence of histamine-mediated negative feedback, 
these primed MCs promoted the expansion of MDSCs, 
which in turn suppressed CD8+ T cells and enhanced 
colorectal carcinogenesis. The production and release of 
Figure 5: MCs support CD11b+Gr1+ MDSCs immunosuppression. A. Co-culture of BMMCs and splenocytes from HDC−/− 
mice in the presence of OVA323–339 peptide. 96 h after culture, CD11b+Gr1+ cells were sorted, expressions of Cox-2, Arg-1 and Ki67 were 
determined by qRT-PCR. B. Supernatant IL-17 was determined by ELISA. C. Representative flow plots show the frequency of CD3+CD8+ 
cytotoxic T cell in tumor margin colon tissue (n = 3). Data are representative from 3 independent experiments.
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histamine by MDSC and MCs, respectively, represents 
an important brake on MDSCs and MC in intestinal 
allergy (Figure 6). This may be a central mechanism in 
atopic patients developing colorectal cancer, and thus a 
potential target for prevention and therapy of intestinal 
malignancy.
Previous studies have demonstrated that HDC 
expression defines the majority of CD11b+Gr1+ MDSCs. 
HDC-EGFP is also expressed in the majority of IMCs in 
normal (non tumor-bearing) mice, and these myeloid cells 
represent the primary site of histamine synthesis. While 
MCs do not express HDC-EGFP or synthesize histamine, 
Figure 6: Schematic comparison of changes in HDC−/− vs WT intestine immunity during OVA allergy and following 
carcinogenesis. A. In WT gut, releasing of histamine supports the normal innate allergic reactions and adoptive T helper cell activation, 
therefore regulates MC function through feedback manner, which maintains the homeostasis of the gut immunity. B. Under histamine 
deficiency, proinflammatory IL-17 produced by MCs augments MDSCs, in particular, upregulates Arg-1 and Cox-2 in MDSCs, thus 
promotes colorectal carcinogenesis.
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they take up and store histamine, and release it in response 
to acute allergic stimuli [28]. MCs, however, do express 
histamine receptors and are thought to be tightly regulated 
by histamine [34, 42, 43, 46]. Thus, in HDC deficient mice 
that have low levels of circulating histamine, we show that 
OVA immunization leads to an expansion of intestinal 
IL-17 expressing MCs. This abnormal accumulation 
of IL-17-secreting MCs was clearly due to histamine 
deficiency, since adding exogenous histamine in vivo 
reduced MC numbers and serum IL-17 levels, and also 
reduced IL-17 secretion in ex vivo cultures. In addition, 
these abnormalities could be rescued by adoptive transfer 
of MCs from HDC competent hematopoietic cells.
The inflammatory cytokine IL-17, which is 
significantly elevated in gastrointestinal inflammation 
and cancer, was originally attributed primarily to a T 
cell (TH17) response [49, 50]. However, more recently, 
several types of innate immune cells have been found to 
be additional sources of IL-17 production in the regulation 
of gut immunity and gastrointestinal cancer [51, 52]. In 
human esophageal squamous cell carcinoma (ESCC), 
MCs were identified as the predominant IL-17 expressing 
cell type by immune microscopy [23]. In the intestine 
of OVA immunized HDC−/− mice, the expression level 
of IL-17 was exclusively elevated in sorted MCs but 
not in either CD4 or CD8 T cells. Thus, in the setting of 
histamine deficiency, MC cells are polarized into IL-17 
secreting cells.
IL-17 production in MCs was associated with 
an accumulation of MDSCs. Previous studies have 
suggested a causal relationship between IL-17 production 
and the level of circulating MDSCs [18, 50, 53]. During 
parasitic infection, MCs are thought to stimulate 
responses by immature myeloid cells, helping to mobilize 
CD11b+Gr1+ cells to assist with the clearance of 
parasites [11]. Thus, it appears that the IL-17-expressing 
subset of MCs expanded in the setting of histamine 
deficiency is particularly effective in mobilizing and 
recruiting cancer-promoting MDSCs to the intestinal 
mucosa. OVA immunization of HDC−/− mice implanted 
with MC38 colon cancer cells led to significantly larger 
tumors with increased numbers of MCs and MDSCs. 
In the AOM/DSS colon carcinogenesis model, OVA 
immunization led to increased MCs and MDSCs, and 
increased colorectal tumors, which correlated with a 
reduction in CD8+ T cells.
Tumor-infiltrating MCs have been implicated 
in CRC pathogenesis and are associated with a poor 
prognosis in human colon cancer patients [54, 55]. 
In mouse models of inflammation-associated colonic 
cancer, MCs are abundant in the tumor tissue; in contrast, 
MC-deficient mice are protected from colitis-associated 
colorectal carcinogenesis [3]. In our study, we observed 
an accumulation of tumor-associated MCs in response 
to immunization and intestinal allergy in HDC−/− mice, 
which supports the notion that MC acts as an important 
modulator in mouse enteric allergy and prolonged allergic 
inflammation-associated carcinogenesis.
A number of questions remain regarding the 
relationships between food allergy and cancer, with 
contrasting observations noted in epidemiologic studies 
[29, 30, 56–59]. On the one hand, allergic reactions 
strengthen host immunity that provides a strong 
defense against attack from invading pathogens and 
aberrant cells, which likely enhances cancer immune 
surveillance [60]. In this sense, allergic responses 
support protective innate immune responses and 
T helper cell polarization [61]. On the other hand, 
some studies have suggested that prolonged host 
allergic immunity associated with the accumulation 
of chronic pro-inflammatory myeloid cells might 
predispose to tumor development [59]. We and 
others have previously shown a regulatory role for 
histamine in the differentiation of immature innate 
myeloid cells. In addition, mice deficient in histamine 
exhibit accelerated tumor progression, and epigenetic 
downregulation of HDC expression in CD11b+Gr1+ 
cells is associated with carcinogenesis [28]. Given the 
pivotal role of histamine in both allergy and cancer, 
our results suggest that histamine-mediated MC 
differentiation may critically link the two disorders.
In histamine deficient gut immunity, OVA allergic 
MCs promote tumorigenesis through the production of the 
proinflammatory cytokine IL-17, expansion of MDSCs and 
reduced activity of tumoricidal CD8+ T cells. Restoring 
histamine downregulates this pathway (Figure 6). 
Further studies will be needed to address whether 
histamine or histamine analogues could be used as a 
novel immune modulating cancer therapy, or if histamine 
receptor antagonism may be detrimental in certain patients 
at high risk for colorectal cancer.
MATERIALS AND METHODS
Mice
All animals were maintained under specific 
pathogen-free (SPF) conditions. 6–8 week age female 
mice: C57BL/6 WT mice, HDC-EGFP (C57BL/6 
background, HDC+/+), HDC−/− mice (C57BL/6 
background) in which intron 5 and exon 6 were replaced 
with a neomycin cassette, and HDC−/−;HDC-EGFP 
(C57BL/6 background, generated by crossing C57BL/6 
HDC-EGFP mice with C57BL/6 HDC−/− mice) were 
involved in this study [28, 42]. In OVA immunization 
experiment, mice were administrated orally (i.g., 30 μg) 
and intraperitoneally (i.p., 50 μg) without adjuvant each 
day for 10 consecutive days. All experiment protocols 
were approved by the Institutional Animal Care and Use 
Committee (IACUC) of Columbia University.
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Antibodies and reagents
OVA, histamine, and AOM were purchased from 
Sigma-Aldrich. OVA peptide (OVA323–339: ISQAVHA-
AHA EINEAGR) was obtained from AnaSpec. DSS was 
obtained from MP Biomedical. Anti-mast cell tryptase 
mouse monoclonal antibody was obtained from Abcam. 
Antibodies used for flow cytometry analysis and cell 
sorting and IL-17 immunofluorescence staining were 
obtained from Biolegend, including FCεRIα (MAR-1), 
c-kit (2B8), CD3 (17A2), CD4 (GK1.5), CD8 (53–6.7), 
CD11b (M1/70), Gr1 (8C5), and IL17a (TC11–18H10.1).
Real-time quantitative RT-PCR and primers
PureLink® RNA Mini Kit or RNAqueous®-Micro 
Total RNA Isolation Kit were used for tissue RNA or 
sorted cell RNA isolation. cDNA was synthesized by 
using SuperScript® III First-Strand Synthesis System 
(Life Technologies, Grand Island, NY). Gene expression 
was determined using FastStart Universal SYBR Green 
or Probe Real-time qRT-PCR (Roche Applied Science, 
Indianapolis, IN). PrimeTime qRT-PCR Assays (Integrated 
DNA Technologies, Coralville, Iowa) were performed 
to measure mouse IL-17a (Mm.PT.56a.6531092) and 
Ki67 (Mm.PT.51.13130770) gene expression. Mouse 
GAPDH (Mm.PT.39a.1) was used as internal control. The 
sequences of primers for SYBR Green qRT-PCR are listed 
in Supplementary Table S1. Applied Biosystems Prism 
9700 PCR machine (Applied Biosystems) was used for all 
real-time PCR experiments.
Cell culture
Mouse BMMCs were differentiated in vitro 
from isolated WT or HDC−/− mice tibia and femur 
bone marrow cells in RPMI 1640 medium (Invitrogen) 
supplemented with 1 mM sodium pyruvate (Gibco), 1 mM 
HEPES (Invitrogen), 2 mM L-glutamine, 1% penicillin-
streptomycin (Gibco), and 10% fetal calf serum (FCS, 
Gibco), with the presence of 1 ng/ml recombinant mouse 
IL-3 (Biolegend) and 10 ng/ml mouse SCF (Biolegend). 
The percentage of MCs was determined by flow cytometry 
after 4 weeks of differentiation. Purity >95% FCεRIα+c-
kit+ BMMCs were subjected to further experiments. 
In some experiments, BMMCs were co-cultured with 
HDC−/− splenocytes in the presence of 10 ng/ml GM-
CSF (Biolegend); 5 × 10−6 M histamine and/or 5 μg/ml 
OVA323–339 peptide was added respectively for additional 
96 h culture.
BMMC adoptive transfer
Differentiated BMMCs from WT or HDC−/− mice 
bone marrow cells were injected intravenously into syngeneic 
HDC−/− mice. OVA was administrated orally (30 μg) and 
intraperitoneally (50 μg) one day after MC transfer. 10 d after, 
mice were killed and exanimated form IL-17 expression.
Flow cytometry
Intraepithelial lymphocytes (IELs) were prepared 
from small intestine jejunum by twice 15 min mechanical 
vibrating in HBSS (Gibco) medium supplemented with 5% 
FBS, 2 mM EDTA (Invitrogen), 0.15 mg/ml DTT (Sigma-
Aldrich), and 10 mM HEPES (Invitrogen). Small intestine 
Lamina propria (LP), colon and colon tumor tissue were 
digested respectively with collagenase IV (Worthington 
Biochemical Corp, Lakewood, NJ), dispase II (Gibco), and 
DNAse I (Roche). The resulting cells were subjected to 40% 
and 80% Percoll gradient (GE Healthcare, Pittsburgh, PA) 
centrifugation to enrich the mononuclear leucocytes. Blood 
and spleen cells were treated with red blood cell (RBC) 
lysis solution (Biolegend). Cells from pooled LP and IEL, 
blood, spleen, and bone marrow cells were passed through a 
70 μm cell strainer to prepare monolayer cell suspension for 
multi-color flow cytometry antibodies staining and analysis. 
Flow cytometry was performed on LSRII flow cytometer 
(BD biosciences). Data were analyzed and presented using 
Flowjo 9 software (Tree Star, Ashland, OR). In some 
experiments, FCεRIα+c-kit+, CD3+CD4+, CD3+CD8+, or 
CD11b+Gr1+ cells were sorted from FACSAria cell sorter 
(BD bioscience) for further experiments.
ELISA
Mice were bled from the submandibular veins. Sera 
were separated by Microtainer tube with serum separator 
(BD, Franklin Lakes, NJ). The concentration of serum IL-4 
or IL-17, and cell culture supernatant IL-17 were determined 
using mouse IL-4 or IL-17a ELISA MAX™ Deluxe kit 
(Biolegend) following the manufacturer’s protocol. Serum 
OVA specific IgE was evaluated with Biolegend LEGEND 
MAX™ Mouse OVA Specific IgE ELISA Kit.
Immunofluorescence staining and histological 
analysis
Mice small intestinal and colonic tissue samples 
were collected and fixed with 4% (w/v) paraformaldehyde 
(PFA) and cryoprotected with 30% (w/v) sucrose for 
making tissue frozen sections. For paraffin sections, 
tissue samples were fixed with 10% (w/v) formalin and 
dehydrated in 70% ethanol. For mast cell tryptase staining, 
frozen sections were first treated with Mouse on Mouse 
(M.O.M.) Fluorescein Kit (Vector), and then stained 
with primary antibody (mouse tryptase, Abcam) and 
secondary antibody (Goat anti-Mouse IgG, Alexa Fluor® 
594 conjugate, Life technologies). IL-17a was stained by 
a FITC-conjugated monoclonal antibody (Biolegend). 




Data were presented as means ± SEMs. Statistic 
differences between different groups were assessed by 
two-tailed Student’s t test with the GraphPad Prism 5 
program (GraphPad Software, San Diego, CA). P < 0.05 
was considered to be statistically significant (*, P < 0.05; 
**, P < 0.01; ***, P < 0.001).
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